All In Biotech

Drug Trial Radar · NCT04384367

Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine

A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,068 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,068

Actual

Start

Dec 30, 2022

Primary completion

Oct 30, 2024

Study completion Nov 30, 2024

Sponsor

Lead sponsor
Eurofarma Laboratorios S.A.Industry
Sponsor type
Industry
First posted
May 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Conditions

  • Migraine

Interventions

  • Rizatriptan 10 mg + Naproxen 550mgDrug

    oral - single dose

  • Maxalt 10Mg TabletDrug

    oral - single dose

  • Flanax 550mgDrug

    oral - single dose

  • Placebo oral tabletDrug

    oral - single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 2-hour pain-freeTime frame: 11 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Eurofarma Laboratorios S.A

    São Paulo, São Paulo, Brazil

  • CEPIC

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.